![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Purpose: There are no clinical studies directly comparing anionic and cationic emulsions of cyclosporine for the treatment of dry eye disease (DED). We therefore conducted a literature review to evaluate the efficacy and safety of these different formulations.
Methods: A literature search was performed in Embase and Medline from January 1999 to May 2019 to identify publications that evaluated clinical outcomes with either cyclosporine anionic or cationic emulsion in patients with moderate-to-severe or severe DED.
Results: Thirteen publications met criteria. In patients with moderate-to-severe disease, evidence demonstrated improvement in the signs of DED with both formulations. However, improvement in symptoms was not consistently demonstrated. Studies specifically in severe DED were only identified with the cationic emulsion and showed improvement in the objective signs of DED. There were no obvious differences in tolerability between products.
Conclusions: Both formulations are effective for the treatment of moderate-to-severe DED and are well tolerated.
Acknowledgments
The authors would like to thank Kendra Hughes, PharmD, and Kim Poinsett-Holmes, PharmD (Evidera, Morrisville, NC), for medical writing services, funded by Santen Pharmaceutical Asia Pte. Ltd. Singapore.
Declaration of interest
LT has received previous research grants, served on advisory boards and/or received travel sponsorship from Alcon-Novartis, Allergan, Santen, Bausch and Lomb, Shire, LF Asia. CB is a consultant for Alcon, Allergan, Dompé, Horus Pharma, Santen, Sifi, and Théa Pharmaceuticals and has received research grants from Horus Pharma, Santen, and Théa Pharmaceuticals. RLBS is a member of the Santen Pharmaceutical Scientific Steering Committee and Speaker Bureau. CCS, VP and KCY declare no conflicts of interest.